Reuters logo
BRIEF-GSK announces positive results from two phase III studies of Incruse Ellipta
June 11, 2014 / 11:51 AM / 3 years ago

BRIEF-GSK announces positive results from two phase III studies of Incruse Ellipta

June 11 (Reuters) - Glaxosmithkline Plc

* Incruse ellipta positive data studies

* GSK and Theravance announce positive data from two studies evaluating efficacy and safety of incruse  ellipta  when added to Relvar  /Breo  Ellipta  in patients with COPD

* Studies showed that for primary endpoint of trough fev1 at day 85, addition of umec 62.5mcg or umec 125mcg to ff/vi 100/25mcg resulted in a statistically significant improvement in lung function when compared with ff/vi 100/25mcg plus placebo in patients with copd. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below